NCT03182426View on ClinicalTrials.gov

Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 15, 2017

Primary Completion Date

July 15, 2024

Study Completion Date

July 15, 2024

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

Plerixafor

Systemic CD34+ stem cell mobilization for beta-cell repair

DRUG

Alemtuzumab

T-cell depletion

DRUG

Anakinra

Anti-inflammatory

DRUG

Etanercept

Anti-inflammatory

DRUG

Liraglutide

Beta-cell regeneration

Trial Locations (1)

T6G 2C8

University of Alberta, Edmonton

Sponsors
All Listed Sponsors
collaborator

Alberta Innovates Health Solutions

OTHER

lead

University of Alberta

OTHER